LU92782I2 - Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson - Google Patents

Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson Download PDF

Info

Publication number: LU92782I2
Authority: LU; Luxembourg
Prior art keywords: safinamide; levodopa; pdi; parkinson; drugs
Prior art date: 2003-04-11

Application number

LU92782C

Other languages

English (en)

Original Assignee

Newron Pharm Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-04-11

Filing date

2015-07-22

Publication date

2015-09-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33159845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92782(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-07-22 Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa

2015-09-22 Publication of LU92782I2 publication Critical patent/LU92782I2/fr

Links

WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
208000018737 Parkinson disease Diseases 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
229960004502 levodopa Drugs 0.000 title 1
NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 title 1
229950002652 safinamide Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LU92782C 2003-04-11 2015-07-22 Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson LU92782I2 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US46220503P	2003-04-11	2003-04-11

Publications (1)

Publication Number	Publication Date
LU92782I2 true LU92782I2 (fr)	2015-09-22

Family

ID=33159845

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92782C LU92782I2 (fr)	2003-04-11	2015-07-22	Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson

Country Status (28)

Country	Link
US (3)	US8283380B2 (fr)
EP (2)	EP2070526B1 (fr)
JP (2)	JP2006522800A (fr)
KR (2)	KR101129015B1 (fr)
CN (2)	CN102274517B (fr)
AR (1)	AR044007A1 (fr)
AT (1)	ATE435012T1 (fr)
AU (1)	AU2004228782B2 (fr)
BR (1)	BRPI0409364A (fr)
CA (1)	CA2523188C (fr)
CY (3)	CY1109295T1 (fr)
DE (1)	DE602004021790D1 (fr)
DK (2)	DK2070526T3 (fr)
ES (2)	ES2326373T3 (fr)
FR (1)	FR15C0054I2 (fr)
HU (1)	HUS1500043I1 (fr)
IL (2)	IL171331A (fr)
LU (1)	LU92782I2 (fr)
MX (1)	MXPA05010873A (fr)
NL (1)	NL300752I2 (fr)
NO (3)	NO334316B1 (fr)
NZ (1)	NZ542910A (fr)
PL (2)	PL1613296T3 (fr)
PT (2)	PT2070526E (fr)
RU (1)	RU2342929C2 (fr)
SI (2)	SI1613296T1 (fr)
TW (1)	TWI340640B (fr)
WO (1)	WO2004089353A2 (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
CA2459470C (fr) *	2001-09-03	2010-10-12	Patricia Salvati	Composition pharmaceutique comprenant de la gabapentine ou un analogue de celle-ci et un .alpha.-aminoamide, et utilisation analgesique de ladite composition
EP1438956A1 (fr) *	2003-01-16	2004-07-21	Newron Pharmaceuticals S.p.A.	Dérivés alpha-aminoamides en tant qu'agents antimigraine
NZ545502A (en) *	2003-08-25	2010-04-30	Newron Pharm Spa	Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1588704A1 (fr)	2004-04-22	2005-10-26	Newron Pharmaceuticals S.p.A.	Dérivés d'alpha-aminoamides utiles dans le traitement de l'acroparesthésie nocturne et des troubles de toxicomanie
JP5319920B2 (ja) *	2004-09-10	2013-10-16	ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー	ナトリウムおよび／またはカルシウムチャンネル選択的調節因子として活性のある医薬の製造のための（ハロベンジルオキシ）ベンジルアミノ−プロパンアミドの使用
US20070004639A1 (en) *	2005-07-01	2007-01-04	Bodybio, Inc.	Methods and compositions for treating Parkinson's disease
US8772346B2 (en)	2005-11-09	2014-07-08	Torrent Pharmaceuticals Limited	Pharmaceutical composition
JP5271087B2 (ja) *	2005-12-22	2013-08-21	ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー	カルシウム及び／又はナトリウムチャネル調節物質としての２−フェニルエチルアミノ誘導体
CN101032474B (zh) *	2006-03-06	2011-02-16	重庆医药工业研究院有限责任公司	一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
EP1870097A1 (fr) *	2006-06-15	2007-12-26	Newron Pharmaceuticals S.p.A.	Dérivés d'alpha-aminoamide pour le traitement de troubles cognitifs
US8106056B2 (en) *	2006-06-16	2012-01-31	Solvay Pharmaceuticals B.V.	Combination preparations comprising bifeprunox and a dopamine agonist
CN101472880B (zh)	2006-06-19	2013-04-24	纽朗制药有限公司	生产2-[4-(3-和2-氟苄氧基)苄氨基]丙酰胺类的方法
DE102007014947B4 (de) *	2007-03-23	2010-05-27	Axxonis Pharma Ag	Stabilisierte wässrige Lösungen von Ergolinverbindungen
EP2150239A1 (fr) *	2007-04-24	2010-02-10	Boehringer Ingelheim International GmbH	Combinaison comprenant une préparation de comprimés à libération prolongée, contenant du pramipexole ou un de ses sels pharmaceutiquement acceptable
PL2155663T3 (pl) *	2007-06-15	2018-06-29	Newron Pharmaceuticals S.P.A.	Podstawione pochodne 2-[2-(fenylo)etyloamino]alkanoamidu oraz ich zastosowanie jako modulatorów kanałów sodowych i (lub) wapniowych
GB2453770A (en) *	2007-10-19	2009-04-22	Reckitt Benckiser Healthcare	Oral composition comprising a cooling agent
WO2009054964A1 (fr) *	2007-10-22	2009-04-30	Concert Pharmaceuticals, Inc.	Dérivés alpha-aminoamides
EA019898B1 (ru)	2007-12-11	2014-07-30	Ньюрон Фармасьютикалс С.П.А.	Способ получения 2-[4-(3- или 2-фторбензилокси)бензиламино]пропанамидов с высокой степенью чистоты
KR101500962B1 (ko) *	2007-12-19	2015-03-10	뉴론 파마슈티칼즈 에스. 피. 에이.	정신 장애의 치료에 유용한 알파아미노아미드 유도체
WO2009122351A2 (fr) *	2008-04-01	2009-10-08	Kangwon National University	Composés antiparkinsoniens mppe
CN102123980B (zh)	2008-06-02	2014-05-07	基因里克斯(英国)有限公司	用于制备对映异构纯胺的方法
EP2280929B1 (fr) *	2008-06-02	2018-01-31	Generics [UK] Limited	Methode amelioree de preparation de rasagiline
EP2303330B2 (fr) *	2008-06-06	2021-06-16	Pharma Two B Ltd.	Compositions pharmaceutiques pour le traitement de la maladie de parkinson
EA201170018A1 (ru) *	2008-06-13	2011-08-30	Тева Фармасьютикал Индастриз, Лтд.	Разагилин для изменения течения болезни паркинсона
WO2010010138A1 (fr) *	2008-07-24	2010-01-28	Boehringer Ingelheim International Gmbh	Composition pharmaceutique renfermant du pramipexole et un inhibiteur des canaux calciques pour le traitement de la maladie de parkinson
US8080584B2 (en) *	2009-01-23	2011-12-20	Teva Pharmaceuticals Industries, Ltd.	Delayed release rasagiline citrate formulation
EP2218444A3 (fr) *	2009-01-23	2010-08-25	Teva Pharmaceutical Industries, Ltd.	Formulation de rasagiline à libération retardée
EP2314569A1 (fr)	2009-10-22	2011-04-27	Merck Patent GmbH	Nouvelles formules polymorphiques de sel de mesylate (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide, et son procédé de fabrication
CN102048717B (zh) *	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
WO2011098456A1 (fr)	2010-02-09	2011-08-18	Merck Serono S.A.	Safinamide dans le traitement de la dyskinésie
BR112012027623B1 (pt)	2010-04-27	2021-07-06	Newron Pharmaceuticals S.P.A.	Processo para a produção de sais de ralfinamida metanossulfonato ou seus renantiômeros, forma pseudopolimorfa de hemi-hidrato cristalino h do sal de metanossulfonato de ralfinamida, ou seu r-enantiômero, seu uso e formulação farmacêutica que o compreende
CN108186611A (zh)	2010-04-30	2018-06-22	帝国制药美国公司	丙炔基氨基茚满透皮组合物
WO2012129429A2 (fr)	2011-03-24	2012-09-27	Teikoku Pharma Usa, Inc.	Compositions transdermiques comprenant une couche d'agent actif et une couche de conversion d'agent actif
WO2013028639A1 (fr)	2011-08-19	2013-02-28	The Trustees Of Princeton University	Formation de liaison c-halogène
US20150031768A1 (en) *	2011-08-19	2015-01-29	The Trustees Of Princeton University	C-halogen bond formation
WO2013070526A1 (fr)	2011-11-09	2013-05-16	Teikoku Pharma Usa, Inc.	Méthodes pour le traitement de tumeurs de la peau
CN104884046A (zh)	2012-10-22	2015-09-02	丝维塔斯治疗公司	用于快速缓解帕金森病的左旋多巴制剂
US9205061B2 (en)	2012-11-02	2015-12-08	Teikoku Pharma Usa, Inc.	Propynylaminoindan transdermal compositions
US9155695B2 (en)	2013-03-14	2015-10-13	Medtronic, Inc.	Injectable ropinirole compositions and methods for making and using same
KR20160026897A (ko)	2013-06-27	2016-03-09	세다르스-신나이 메디칼 센터	신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제
JP2017513866A (ja) *	2014-04-21	2017-06-01	サイヴィタスセラピューティックス，インコーポレイテッド	パーキンソン病の運動症状変動の迅速な緩和
JP6446131B2 (ja)	2014-10-02	2018-12-26	メガバイオウッドカンパニー，リミテッド	α−アミノアミド誘導体化合物及びこれを含む薬学的組成物
CN108349993A (zh) *	2015-08-27	2018-07-31	普雷克斯顿医疗股份公司	用于左旋多巴诱导的运动障碍疗法的脑-穿透剂色酮肟衍生物
KR102889062B1 (ko) *	2016-03-17	2025-11-21	더 존스 홉킨스 유니버시티	Paris의 파네실화에 의해 파킨슨병을 예방 또는 치료하기 위한 방법
ITUA20163981A1 (it)	2016-05-31	2017-12-01	Zambon Spa	Composizioni farmaceutiche comprendenti safinamide
WO2018132746A1 (fr) *	2017-01-14	2018-07-19	Mischley Laurie Kathern	Procédé d'utilisation d'excréments et de sécrétions humains pour la détection précoce de la maladie de parkinson
CN109251155A (zh) *	2017-07-14	2019-01-22	广东东阳光药业有限公司	α-氨基酰胺衍生物及其用途
WO2019036624A1 (fr) *	2017-08-17	2019-02-21	Gu Zi Qiang	Agents anti-parkinson de type sels de pamoate de monoamine, leur procédé de préparation et d'utilisation
BR112020008653A2 (pt)	2017-11-02	2020-10-27	Zambon S.P.A.	composições farmacêuticas compreendendo safinamida
KR102005019B1 (ko) *	2018-04-04	2019-07-31	한국과학기술연구원	뇌졸중의 예방 및 치료용 조성물
KR20220074895A (ko) *	2019-09-12	2022-06-03	어치브 라이프 사이언시즈, 인크.	필요로 하는 대상체의 중독 치료 및/또는 예방을 위한 시티신을 포함하는 조성물
LU101477B1 (en) *	2019-11-12	2021-05-14	Univ Luxembourg	An inhibitor of an iron-containing hydrogenase of a methanogenic archaeon for use in the treatment or prevention of a parkinsonian condition
CN110938014A (zh) *	2019-11-28	2020-03-31	岳千奥	取代苯氧酰胺衍生物、应用及用于治疗帕金森病的药物
WO2021109880A1 (fr) *	2019-12-06	2021-06-10	上海医药集团股份有限公司	Composition pharmaceutique, trousse complémentaire et son application
CN110999980A (zh) *	2019-12-19	2020-04-14	新疆石河子职业技术学院（石河子市技工学校）	一种葡萄酒洗浸奶酪加工方法
JP2023538859A (ja) *	2020-08-31	2023-09-12	パーデュー、ファーマ、リミテッド、パートナーシップ	レボドパ送達のための組成物及び方法
JP2024509888A (ja) *	2021-03-08	2024-03-05	プロシーナバイオサイエンシーズリミテッド	パーキンソン病の治療
KR102790040B1 (ko) *	2021-06-24	2025-04-01	연세대학교 산학협력단	도파민 미모톱 기능 합성 펩티드 및 이를 포함하는 mao-b 억제제

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1140748A (en)	1966-06-23	1969-01-22	Ici Ltd	New carboxylic acid derivatives
US3795739A (en) *	1972-02-14	1974-03-05	Hoffmann La Roche	Treatment of parkinson disease
US4049663A (en)	1972-06-06	1977-09-20	Allen & Hanburys Limited	Ethylene diamine derivatives
FR2480747A1 (fr)	1980-04-17	1981-10-23	Roques Bernard	Derives d'acides amines et leur application therapeutique
US4935429A (en)	1985-10-25	1990-06-19	Dackis Charles A	Method of treating psychostimulant addiction
EP0252290B1 (fr) *	1986-06-10	1992-06-03	CHIESI FARMACEUTICI S.p.A.	Compositions pharmaceutiques contenant le lévodopa méthyl ester, leur préparation et leurs applications thérapeutiques
DE58905201D1 (de)	1988-03-01	1993-09-16	Birkmayer Walther	Mittel zur behandlung des parkinson-syndroms.
IL94466A (en) *	1989-05-25	1995-01-24	Erba Carlo Spa	Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) *	1990-05-07	1993-06-22	Alza Corporation	Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5502658A (en)	1990-12-27	1996-03-26	Relin; Arkadi	Sampled-continuous probability method of velocity measurement of the object having informatively-structural inhomogeneity
GB9306886D0 (en)	1993-04-01	1993-05-26	Erba Carlo Spa	Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) *	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
DE69532482T2 (de) *	1995-05-26	2004-11-25	Pfizer Inc.	Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda-antagonisten enthält
GB9515412D0 (en) *	1995-07-27	1995-09-27	Pharmacia Spa	2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
GB9727523D0 (en)	1997-12-31	1998-02-25	Pharmacia & Upjohn Spa	Alpha-aminoamide derivatives useful as analgesic agents
FI109453B (fi)	1999-06-30	2002-08-15	Orion Yhtymae Oyj	Farmaseuttinen koostumus
US20020019421A1 (en) *	2000-07-05	2002-02-14	Roni Biberman	Compositions and therapy for substance addiction
DE10041479A1 (de) *	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923
FR2829027A1 (fr) *	2001-08-29	2003-03-07	Aventis Pharma Sa	Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson

2004
- 2004-04-07 AR ARP040101189A patent/AR044007A1/es unknown
- 2004-04-08 TW TW093109755A patent/TWI340640B/zh not_active IP Right Cessation
- 2004-04-08 PL PL04726590T patent/PL1613296T3/pl unknown
- 2004-04-08 RU RU2005131422/15A patent/RU2342929C2/ru active
- 2004-04-08 CA CA2523188A patent/CA2523188C/fr not_active Expired - Lifetime
- 2004-04-08 KR KR1020057019264A patent/KR101129015B1/ko not_active Expired - Lifetime
- 2004-04-08 PL PL09154864T patent/PL2070526T3/pl unknown
- 2004-04-08 PT PT91548644T patent/PT2070526E/pt unknown
- 2004-04-08 MX MXPA05010873A patent/MXPA05010873A/es active IP Right Grant
- 2004-04-08 NZ NZ542910A patent/NZ542910A/en not_active IP Right Cessation
- 2004-04-08 PT PT04726590T patent/PT1613296E/pt unknown
- 2004-04-08 DK DK09154864.4T patent/DK2070526T3/da active
- 2004-04-08 CN CN201110271872.8A patent/CN102274517B/zh not_active Expired - Lifetime
- 2004-04-08 AT AT04726590T patent/ATE435012T1/de active
- 2004-04-08 JP JP2006506582A patent/JP2006522800A/ja active Pending
- 2004-04-08 US US10/559,982 patent/US8283380B2/en active Active
- 2004-04-08 CN CNA200480009655XA patent/CN1771030A/zh active Pending
- 2004-04-08 ES ES04726590T patent/ES2326373T3/es not_active Expired - Lifetime
- 2004-04-08 AU AU2004228782A patent/AU2004228782B2/en not_active Expired
- 2004-04-08 DK DK04726590T patent/DK1613296T3/da active
- 2004-04-08 KR KR1020117013555A patent/KR20110070929A/ko not_active Ceased
- 2004-04-08 EP EP09154864.4A patent/EP2070526B1/fr not_active Expired - Lifetime
- 2004-04-08 BR BRPI0409364-0A patent/BRPI0409364A/pt not_active Application Discontinuation
- 2004-04-08 SI SI200431192T patent/SI1613296T1/sl unknown
- 2004-04-08 WO PCT/IB2004/001408 patent/WO2004089353A2/fr not_active Ceased
- 2004-04-08 EP EP04726590A patent/EP1613296B1/fr not_active Expired - Lifetime
- 2004-04-08 SI SI200432150T patent/SI2070526T1/sl unknown
- 2004-04-08 ES ES09154864.4T patent/ES2454272T3/es not_active Expired - Lifetime
- 2004-04-08 DE DE602004021790T patent/DE602004021790D1/de not_active Expired - Lifetime
2005
- 2005-10-10 NO NO20054640A patent/NO334316B1/no active Protection Beyond IP Right Term
- 2005-10-10 IL IL171331A patent/IL171331A/en active Protection Beyond IP Right Term
2009
- 2009-08-12 CY CY20091100857T patent/CY1109295T1/el unknown
2011
- 2011-11-17 IL IL216403A patent/IL216403A/en active IP Right Grant
2012
- 2012-08-24 US US13/594,621 patent/US8901176B2/en not_active Expired - Lifetime
- 2012-12-14 JP JP2012273371A patent/JP2013067647A/ja active Pending
2013
- 2013-10-28 NO NO20131417A patent/NO335537B1/no unknown
2014
- 2014-04-15 CY CY20141100288T patent/CY1115286T1/el unknown
- 2014-11-04 US US14/532,925 patent/US9492410B2/en not_active Expired - Fee Related
2015
- 2015-07-01 CY CY2015025C patent/CY2015025I2/el unknown
- 2015-07-17 NL NL300752C patent/NL300752I2/nl unknown
- 2015-07-22 HU HUS1500043C patent/HUS1500043I1/hu unknown
- 2015-07-22 FR FR15C0054C patent/FR15C0054I2/fr active Active
- 2015-07-22 LU LU92782C patent/LU92782I2/fr unknown
- 2015-07-23 NO NO2015018C patent/NO2015018I1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
NO20054640D0 (no)	2005-10-10
TW200505423A (en)	2005-02-16
DK1613296T3 (da)	2009-10-05
FR15C0054I2 (fr)	2018-01-26
DK2070526T3 (da)	2014-03-24
PL2070526T3 (pl)	2014-08-29
NO335537B1 (no)	2014-12-22
CY2015025I1 (el)	2016-04-13
CY1115286T1 (el)	2017-01-04
CA2523188C (fr)	2012-09-25
MXPA05010873A (es)	2006-03-21
ATE435012T1 (de)	2009-07-15
CA2523188A1 (fr)	2004-10-21
KR20110070929A (ko)	2011-06-24
KR101129015B1 (ko)	2012-04-20
CY2015025I2 (el)	2016-04-13
NO20054640L (no)	2005-12-09
US20070093495A1 (en)	2007-04-26
NL300752I2 (fr)	2016-07-05
IL216403A0 (en)	2011-12-29
WO2004089353A2 (fr)	2004-10-21
US9492410B2 (en)	2016-11-15
US8901176B2 (en)	2014-12-02
WO2004089353A8 (fr)	2005-09-01
BRPI0409364A (pt)	2006-04-25
HUS1500043I1 (hu)	2018-11-28
JP2006522800A (ja)	2006-10-05
TWI340640B (en)	2011-04-21
CY1109295T1 (el)	2014-07-02
JP2013067647A (ja)	2013-04-18
IL216403A (en)	2015-01-29
PT2070526E (pt)	2014-03-31
US20130053368A1 (en)	2013-02-28
EP2070526B1 (fr)	2014-02-26
PL1613296T3 (pl)	2009-12-31
AU2004228782A1 (en)	2004-10-21
NO20131417L (no)	2005-12-09
US20150150833A1 (en)	2015-06-04
NO334316B1 (no)	2014-02-03
US8283380B2 (en)	2012-10-09
CN102274517B (zh)	2018-08-31
FR15C0054I1 (fr)	2015-11-09
EP1613296A2 (fr)	2006-01-11
CN102274517A (zh)	2011-12-14
RU2005131422A (ru)	2006-04-27
WO2004089353A3 (fr)	2004-12-16
RU2342929C2 (ru)	2009-01-10
SI1613296T1 (sl)	2009-10-31
IL171331A (en)	2012-03-29
KR20060010745A (ko)	2006-02-02
SI2070526T1 (sl)	2014-05-30
CN1771030A (zh)	2006-05-10
EP2070526A1 (fr)	2009-06-17
NO2015018I2 (no)	2015-07-23
AU2004228782B2 (en)	2010-05-20
EP1613296B1 (fr)	2009-07-01
PT1613296E (pt)	2009-07-30
DE602004021790D1 (de)	2009-08-13
ES2454272T3 (es)	2014-04-10
AR044007A1 (es)	2005-08-24
NO2015018I1 (no)	2015-08-03
NZ542910A (en)	2007-10-26
ES2326373T3 (es)	2009-10-08

Publication	Publication Date	Title
LU92782I2 (fr)	2015-09-22	Safinamide à utiliser en combinaison avec levodopa/PDI, et éventuellement avec d'autres médicaments PD, pour le traitement de la maladie de Parkinson
WO2005034998A3 (fr)	2005-08-11	Procedes et compositions destines au traitement de la douleur et d'autres etats a mediation adrenergique alpha-2
EP1850880A4 (fr)	2010-09-22	Agents therapeutiques a base d'aptameres utiles dans le traitement de troubles lies au complement
IL190150A0 (en)	2008-08-07	New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
EP1676512A3 (fr)	2008-12-10	Articles pour traitement de la peau et méthodes
HRP20130602T1 (en)	2013-07-31	2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
EP2035412A4 (fr)	2011-02-16	Agonistes du récepteur muscarinique convenant au traitement de la douleur, de la maladie d'alzheimer et de la schizophrénie
IL195431A0 (en)	2009-08-03	Muscarinic receptor agonists that are effective in the treatment of pain, alzheimer's disease and schizophrenia
IL177787A0 (en)	2006-12-31	1-aminovyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease
FR2886851B1 (fr)	2007-10-05	Composition a base d'une avermectine et de metronidazole notamment pour le traitement de la rosacee
EP1737428A4 (fr)	2010-12-22	Systemes d'administration macromoleculaires destines a l'imagerie, a l'evaluation et au traitement non invasifs de l'arthrite et d'autres maladies inflammatoires
FR2866340B1 (fr)	2006-11-24	Derives d'oxazole, leur preparation et leur utilisation en therapeutique.
DZ3141A1 (fr)	2001-01-14	Inhibiteurs d'aminotransferase acides aminés-dépendante à chaîne ramifiée, et leur utilisation dans le cadre du traitement de la rétinopathie diabétique.
IL185300A0 (en)	2008-02-09	New pharmaceutical compositions useful in the treatment of parkinson's disease
BRPI0811538A2 (pt)	2015-08-11	Uso de ciclosporinas no tratamento de pacientes com lentes intraoculares.
PL378360A1 (pl)	2006-03-20	Sposób leczenia choroby Parkinsona u ludzi za pomocą infuzji do skorupy czynnika neurotroficznego pochodzącego z gleju
EP1855679A4 (fr)	2014-07-23	Inhibiteurs de la beta-secretase d'aminomethyle dans le traitement de la maladie d'alzheimer
ITRM20050446A1 (it)	2007-02-20	Uso di stilbeni idrossilati e glucosidati per la prevenzione ed il trattamento di patologie oculari.
EP2272497A3 (fr)	2011-03-23	Procédés pour augmenter la fonction lymphatique
FR2886850B1 (fr)	2007-10-05	Composition a base d'une avermectine et de peroxyde de benzoyle notamment pour le traitement de la rosacee
EP2137156A4 (fr)	2011-06-22	Promédicaments biodisponibles par voie orale de (+)-3-hydroxymorphinane utilisés dans la prévention ou le traitement de la maladie de parkinson
WO2006012521A3 (fr)	2006-05-04	Traitement de maladies oculaires
WO2008070311A3 (fr)	2009-01-08	Examen de profil de l'expression génique de la maladie de parkinson
FR2886852B1 (fr)	2007-11-23	Composition a base d'une avermectine et d'hydrocortisone notamment pour le traitement de la rosacee
EA200801890A1 (ru)	2009-04-28	Средство для лечения шума в ушах